Search results for "Lip"

showing 10 items of 8306 documents

Decreases in Circulating Concentrations of Long-Chain Acylcarnitines and Free Fatty Acids During the Glucose Tolerance Test Represent Tissue-Specific…

2019

Background: Insulin plays a pivotal role in the regulation of both carbohydrate and lipid intermediate turnover and metabolism. In the transition from a fasted to fed state, insulin action inhibits lipolysis in adipocytes, and acylcarnitine synthesis in the muscles and heart. The aim of this study was to measure free fatty acid (FFA) and acylcarnitine levels during the glucose tolerance test as indicators of tissue-specific insulin resistance. Results: Insulin release in response to glucose administration decreased both FFA and long-chain acylcarnitine levels in plasma in healthy control animals by 30% (120 min). The glucose tolerance test and [3H]-deoxy-D-glucose uptake in tissues revealed…

0301 basic medicinemedicine.medical_specialtyGlucose uptakemedicine.medical_treatmentEndocrinology Diabetes and MetabolismAdipose tissuelong-chain acylcarnitines030209 endocrinology & metabolismType 2 diabetesglucose tolerance testlcsh:Diseases of the endocrine glands. Clinical endocrinology03 medical and health sciences0302 clinical medicineInsulin resistanceEndocrinologyInternal medicineinsulin resistancemedicineLipolysisOriginal ResearchGlucose tolerance testlcsh:RC648-665medicine.diagnostic_testChemistryInsulinfree fatty acidsmedicine.disease030104 developmental biologyEndocrinologyPostprandialtype 2 diabetesFrontiers in Endocrinology
researchProduct

Altered synaptic phospholipid signaling in PRG-1 deficient mice induces exploratory behavior and motor hyperactivity resembling psychiatric disorders.

2017

Abstract Plasticity related gene 1 (PRG-1) is a neuron specific membrane protein located at the postsynaptic density of glutamatergic synapses. PRG-1 modulates signaling pathways of phosphorylated lipid substrates such as lysophosphatidic acid (LPA). Deletion of PRG-1 increases presynaptic glutamate release probability leading to neuronal over-excitation. However, due to its cortical expression, PRG-1 deficiency leading to increased glutamatergic transmission is supposed to also affect motor pathways. We therefore analyzed the effects of PRG-1 function on exploratory and motor behavior using homozygous PRG-1 knockout (PRG-1−/−) mice and PRG-1/LPA2–receptor double knockout (PRG-1−/−/LPA2−/−)…

0301 basic medicinemedicine.medical_specialtyGlutamic AcidNerve Tissue ProteinsBiologyHyperkinesisHippocampusOpen field03 medical and health sciencesBehavioral NeuroscienceGlutamatergicchemistry.chemical_compoundMice0302 clinical medicineLysophosphatidic acidmedicineAnimalsReceptors Lysophosphatidic AcidPsychiatryMice KnockoutNeuronsMental DisordersGlutamate receptorSomatosensory CortexMice Inbred C57BL030104 developmental biologymedicine.anatomical_structurechemistrySynapsesExploratory BehaviorGABAergicCalmodulin-Binding ProteinsFemaleNeuronSignal transductionLysophospholipidsPostsynaptic density030217 neurology & neurosurgerySignal TransductionBehavioural brain research
researchProduct

Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imb…

2016

Gut microbiota is involved in obesity, metabolic syndrome and the progression of nonalcoholic fatty liver disease (NAFLD). It has been recently suggested that the flavonoid quercetin may have the ability to modulate the intestinal microbiota composition, suggesting a prebiotic capacity which highlights a great therapeutic potential in NAFLD. The present study aims to investigate benefits of experimental treatment with quercetin on gut microbial balance and related gut-liver axis activation in a nutritional animal model of NAFLD associated to obesity. C57BL/6J mice were challenged with high fat diet (HFD) supplemented or not with quercetin for 16 weeks. HFD induced obesity, metabolic syndrom…

0301 basic medicinemedicine.medical_specialtyGut floraDiet High-FatBiochemistryMice03 medical and health sciencesNon-alcoholic Fatty Liver DiseasePhysiology (medical)Internal medicineNonalcoholic fatty liver diseasemedicineAnimalsHumansObesityMetabolic SyndromebiologyFatty liverLipid metabolismLipid Metabolismmedicine.diseasebiology.organism_classificationGastrointestinal MicrobiomeIntestinesToll-Like Receptor 4Disease Models Animal030104 developmental biologyEndocrinologyLiverLipotoxicityImmunologyQuercetinInsulin ResistanceSteatosisMetabolic syndromeDysbiosisSignal TransductionFree Radical Biology and Medicine
researchProduct

Polyphenol-rich and alcoholic beverages and metabolic status in adults living in Sicily, Southern Italy

2021

Polyphenol-rich beverage consumption is not univocally accepted as a risk modulator for cardio-metabolic risk factors, despite mechanistic and epidemiological evidence suggesting otherwise. The aim of this study was to assess whether an association between polyphenol-rich beverage consumption and metabolic status could be observed in a Mediterranean cohort with relatively low intake of tea, coffee, red and white wine, beer, and fresh citrus juice. Demographic and dietary characteristics of 2044 adults living in southern Italy were analyzed. Multivariate logistic regression analyses were used to calculate odds ratios (ORs) and 95% confidence intervals (CIs) of the association between polyphe…

0301 basic medicinemedicine.medical_specialtyHealth (social science)teabeverageschlorogenic acidcoffeeContext (language use)Plant Science030204 cardiovascular system & hematologyhydroxycinnamic acidslcsh:Chemical technologyHealth Professions (miscellaneous)MicrobiologyjuiceArticle03 medical and health sciences0302 clinical medicineEnvironmental healthEpidemiologymedicineflavonoidlcsh:TP1-1185JUICE.Settore MED/49 - Scienze Tecniche Dietetiche Applicatewinepolyphenols030109 nutrition & dieteticsphenolic acidbusiness.industryConfoundingfood and beveragesOdds ratiomedicine.diseaseAlcoholic beverage consumptionpolyphenolWhite WineCohortflavonoidsbeerbusinessphenolic acidsDyslipidemiaFood Science
researchProduct

Bergamot reduces plasma lipids, atherogenic small dense LDL, and subclinical atherosclerosis in subjects with moderate hypercholesterolemia: A 6 mont…

2016

Background: Some patients experience statin-induced side effects or prefer nutraceutical approaches for the treatment of dyslipidemia. This has led to a search for alternative therapeutic approaches for dyslipidemia management. In recent studies Citrus bergamia (known as Bergamot) juice was able to reduce serum levels of lipids. Such benefit may be attributed to high amounts of flavonoids contained in Bergamot fruit juice (neoeriocitrin, neohesperidin, naringin). The aim of the present study was to fully investigate the effects of a Bergamot extract on cardio-metabolic parameters, including plasma lipids, atherogenic lipoproteins and subclinical atherosclerosis. Methods: Eighty subjects (42…

0301 basic medicinemedicine.medical_specialtyHypercholesterolemiaBergamotCarotid IMT030204 cardiovascular system & hematology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineNeoeriocitrinMedicinePharmacology (medical)Prospective cohort studyNaringinOriginal ResearchLDL subclassesPharmacologyNeohesperidinbusiness.industryCholesterollcsh:RM1-950medicine.diseaseCardiovascular risklcsh:Therapeutics. Pharmacology030104 developmental biologyEndocrinologychemistryLow-density lipoproteinlipids (amino acids peptides and proteins)LDL subclassebusinessDyslipidemiaLipoprotein
researchProduct

2018

Patients with inflammatory bowel disease (IBD) are susceptible to thromboembolism. Interestingly, IBD occurs less frequently in patients with inherited bleeding disorders. Therefore, we analyzed whether F9-deficiency is protective against the onset of acute colitis in a genetic hemophilia B mouse model. In the 3.5% dextran sulfate sodium (DSS)-induced colitis model, F9-deficient mice were protected from body-weight loss and had a reduced disease activity score. We detected decreased colonic myeloperoxidase activity and decreased CXCL1 levels in DSS-treated F9-deficient mice compared with wild-type (WT) littermate controls, indicating decreased neutrophil infiltration. Remarkably, we identif…

0301 basic medicinemedicine.medical_specialtyLipopolysaccharideBiologyCoagulation Factor IXmedicine.diseaseIntestinal epitheliumInflammatory bowel diseaseGeneral Biochemistry Genetics and Molecular BiologyCXCL103 medical and health scienceschemistry.chemical_compound030104 developmental biology0302 clinical medicineEndocrinologychemistryInternal medicinemedicine030211 gastroenterology & hepatologyColitisGeneral Agricultural and Biological SciencesReceptorAcute colitisBiology Open
researchProduct

Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: Predictive value of DNA-PK and phosphorylated ACC

2016

// Francesco Perrone 1,* , Gustavo Baldassarre 2,* , Stefano Indraccolo 3,* , Simona Signoriello 4 , Gennaro Chiappetta 1 , Franca Esposito 5 , Gabriella Ferrandina 6 , Renato Franco 1,15 , Delia Mezzanzanica 7 , Maura Sonego 2 , Elisabetta Zulato 3 , Gian F. Zannoni 6 , Vincenzo Canzonieri 2 , Giovanni Scambia 6 , Roberto Sorio 2 , Antonella Savarese 8 , Enrico Breda 9 , Paolo Scollo 10 , Antonella Ferro 11 , Stefano Tamberi 12 , Antonio Febbraro 13 , Donato Natale 14 , Massimo Di Maio 1,16 , Daniela Califano 1 , Giosue  Scognamiglio 1 , Domenica Lorusso 7 , Silvana Canevari 7 , Simona Losito 1 , Ciro Gallo 4,** and Sandro Pignata 1,** 1 Istituto Nazionale per lo Studio e la Cura dei Tumor…

0301 basic medicinemedicine.medical_specialtyLiposomal Doxorubicinovarian cancer; phase 3 clinical trial; predictive factors; pACC; DNA-PKDNA-Activated Protein KinaseDisease-Free Survivalpredictive factorDNA-PK03 medical and health scienceschemistry.chemical_compound0302 clinical medicineOvarian cancerPhase 3 clinical trialAntineoplastic Combined Chemotherapy ProtocolsOverall survivalMedicineHumansDNA-PK; ovarian cancer; pACC; phase 3 clinical trial; predictive factorsGynecologyOvarian NeoplasmsAdvanced ovarian cancerphase 3 clinical trialbusiness.industrySignificant differenceDNA-PK; Ovarian cancer; PACC; Phase 3 clinical trial; Predictive factors; Antineoplastic Combined Chemotherapy Protocols; DNA-Activated Protein Kinase; Disease-Free Survival; Female; Humans; Ovarian Neoplasms; Prognosismedicine.diseasePrognosisPredictive valuePACCCarboplatinhumanitiesFirst line treatmentovarian cancer030104 developmental biologyOncologychemistry030220 oncology & carcinogenesisFemalebusinessOvarian cancerPredictive factorsResearch PaperpACC
researchProduct

Diet, weight loss, and liver health in nonalcoholic fatty liver disease: Pathophysiology, evidence, and practice.

2015

Fatty liver accumulation results from an imbalance between lipid deposition and removal, driven by the hepatic synthesis of triglycerides and de novo lipogenesis. The habitual diet plays a relevant role in the pathogenesis of nonalcoholic fatty liver disease (NAFLD), and both risky (e.g., fructose) and protective foods (Mediterranean diet) have been described, but the contribution of excess calories remains pivotal. Accordingly, weight loss is the most effective way to promote liver fat removal. Several controlled studies have confirmed that an intense approach to lifestyle changes, carried on along the lines of cognitive-behavior treatment, is able to attain the desired 7%-10% weight loss,…

0301 basic medicinemedicine.medical_specialtyMediterranean diet03 medical and health sciences0302 clinical medicineFibrosisWeight lossNon-alcoholic Fatty Liver DiseaseRisk FactorsInternal medicineNonalcoholic fatty liver diseaseWeight LossmedicineHumansExerciseHepatologybusiness.industryFatty liverLipid metabolismHepatologymedicine.diseaseLipid MetabolismDiet030104 developmental biologyEndocrinologyLiverLipogenesis030211 gastroenterology & hepatologymedicine.symptomSedentary BehaviorbusinessHepatology (Baltimore, Md.)
researchProduct

Long-Term Aspartame Administration Leads to Fibrosis, Inflammasome Activation, and Gluconeogenesis Impairment in the Liver of Mice

2021

Background: Aspartame is an artificial sweetener used in foods and beverages worldwide. However, it is linked to oxidative stress, inflammation, and liver damage through mechanisms that are not fully elucidated yet. This work aimed to investigate the effects of long-term administration of aspartame on the oxidative and inflammatory mechanisms associated with liver fibrosis progression in mice. Methods: Mice were divided into two groups with six animals each: control and aspartame. Aspartame (80 mg/kg, via oral) or vehicle was administrated for 12 weeks. Results: Aspartame caused liver damage and elevated serum transaminase levels. Aspartame also generated liver fibrosis, as evidenced by his…

0301 basic medicinemedicine.medical_specialtyPGC-1αInflammationBiologymedicine.disease_causeGeneral Biochemistry Genetics and Molecular BiologyArticleaspartameNrf2Lipid peroxidation03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDownregulation and upregulationFibrosislipidinflammasomeInternal medicinemedicinelcsh:QH301-705.5liver fibrosisGeneral Immunology and MicrobiologyAspartameInflammasomelipid peroxidationmedicine.diseaseCollagen type I alpha 1030104 developmental biologyEndocrinologyhypoglycemiagluconeogenesischemistrylcsh:Biology (General)030211 gastroenterology & hepatologymedicine.symptomGeneral Agricultural and Biological SciencesOxidative stressmedicine.drugBiology
researchProduct

Clinical reappraisal of SHORT syndrome withPIK3R1mutations: toward recommendation for molecular testing and management

2015

SHORT syndrome has historically been defined by its acronym: short stature (S), hyperextensibility of joints and/or inguinal hernia (H), ocular depression (O), Rieger abnormality (R) and teething delay (T). More recently several research groups have identified PIK3R1 mutations as responsible for SHORT syndrome. Knowledge of the molecular etiology of SHORT syndrome has permitted a reassessment of the clinical phenotype. The detailed phenotypes of 32 individuals with SHORT syndrome and PIK3R1 mutation, including eight newly ascertained individuals, were studied to fully define the syndrome and the indications for PIK3R1 testing. The major features described in the SHORT acronym were not unive…

0301 basic medicinemedicine.medical_specialtyPediatricsTeethingbusiness.industryIntrauterine growth restrictionmedicine.diseaseShort stature3. Good health03 medical and health sciencesInguinal hernia030104 developmental biologyEndocrinologySHORT syndromeInternal medicineSpeech delayGeneticsEtiologymedicinemedicine.symptombusinessLipoatrophyGenetics (clinical)Clinical Genetics
researchProduct